resiquimod has been researched along with Neoplasm Metastasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Li, N; Li, P; Lu, Q; Qi, S; Song, Y; Tan, F; Wang, S; Wang, Y; Yang, L; Yang, S | 1 |
| Chen, Q; Su, X; Wang, J; Xie, X; Zeng, S; Zhang, L | 1 |
2 other study(ies) available for resiquimod and Neoplasm Metastasis
| Article | Year |
|---|---|
Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Topics: Animals; B7-H1 Antigen; Carbon; Cell Line, Tumor; Drug Carriers; Imidazoles; Immunotherapy; Indoles; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Phototherapy; Polyethylene Glycols; Polymers; Temperature | 2019 |
Bioresorbable Depot for Sustained Release of Immunostimulatory Resiquimod in Suppressing Both Primary Triple-Negative Breast Tumors and Metastatic Occurrence.
Topics: Adjuvants, Immunologic; Cell Line, Tumor; Delayed-Action Preparations; Humans; Imidazoles; Neoplasm Metastasis; Precision Medicine; Triple Negative Breast Neoplasms | 2021 |